GRI Bio, Inc. (GRI)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Albert Agro Ph.d. | Co-Founder & Chief Medical Officer | 461.1k | -- | 1965 |
Ms. Leanne M. Kelly | CFO & Corporate Secretary | 550.93k | -- | 1977 |
Ms. Cristina Gil White | Interim Chief Executive Officer | -- | -- | -- |
Dr. Vipin Kumar Chaturvedi Ph.D. | Co-Founder & Chief Scientific Officer | -- | -- | 1959 |
GRI Bio, Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 4
Description
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Corporate Governance
Upcoming Events
November 12, 2024 at 9:00 PM UTC - November 18, 2024 at 9:00 PM UTC
GRI Bio, Inc. Earnings Date